BMO Lifts Biogen Price Target to $196, Cites High-Dose Spinraza and SLE Readouts
BMO Capital has raised its price target for Biogen Inc. to $196 from $165 while keeping a Market Perform rating, pointing to increased confidence in high-dose Spinraza and anticipated litifilimab trial readouts in systemic lupus erythematosus. The firm balanced that optimism against an expected decline in multiple sclerosis revenue in 2026 and mixe…